arrowHome arrow News arrow Bioinformatics Companies arrow Genomics Collaborative,Inc
Newsflash

Genehelix brings a large database of Bioinformatics companies and institutes with complete profiles and current job openings . Search here for your company profile...

Main Menu
Home
FAQ
Contact Us
Search
Wrapper
Drug design
News
Tools
Proteomics
Genomics
Software
Cheminformatics
Databases
Books
Group
Articles
Online Tutorials
Companies-Software-1
DNA-PROTEIN-ANALYSIS
Bioinformatics Course
About Us
Login Form
Username

Password

Remember me
Forgotten your password?
No account yet? Create one
Genomics Collaborative,Inc PDF Print E-mail

Genomics Collaborative, Inc.

Genomics Collaborative, Inc ("GCI") was acquired by SeraCare Life
Sciences in June of 2004.

GCI has developed expertise in applying the science of human genetics to drug and diagnostic discovery decisions. The Company's approach links human genes, proteins, and clinical outcomes through proprietary technology platforms. GCI's state-of-the-art technology offers a highly efficient method to validate genomics-based drug and diagnostic targets, and has already been validated through partnerships with more than 30 pharmaceutical and biotechnology companies. GCI believes that to broadly apply targets to drug or diagnostic development in the pharmaceutical market, they must be validated in human populations.

The Company provides a powerful combination of resources through its target validation program, GCI Access™. First, the program offers customized access to GCI's Global Repository™ of appropriately consented clinical research material. This includes human DNA, RNA, sera, and snap-frozen tissue samples linked to detailed medical information collected from patient populations worldwide. To date, the Company has recruited over 120,000 patients in building Global Repository™, and prospective collections continue in various disease states. Additionally, the GCI Access™ program offers customers expertise in proficiently designing and conducting human genetic studies geared towards the development of therapeutics and diagnostics.

Together with its study design, statistics, and analysis capabilities, GCI offers a suite of high throughput genomic analysis tools, including: SNP genotyping, DNA sequencing, RT-PCR, and gene expression analyses. These tools can be applied to leverage the assets of the Company's Global Repository™ in research settings. This combination places GCI at the forefront of the next generation of target validation and drug discovery.
 

Jobs in GCI click here

Cambridge Headquarters and Repository/Laboratory

99 Erie Street
Cambridge, MA 02139, USA
Phone: 617.661.2400
Toll free: 1.877.GENOMIX (436-6649)
Fax: 617.661.8899
 

< Prev   Next >